[Skip to Navigation]
Sign In
Comment & Response
October 2018

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

Nathan I. Cherny, MBBS, FRACP, FRCP, LLD1; Elisabeth G. E. de Vries, MD, PhD2; For the European Society for Medical Oncology Magnitude of Clinical Benefit Scale Working Group
Author Affiliations
  • 1Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel
  • 2Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
JAMA Oncol. 2018;4(10):1437. doi:10.1001/jamaoncol.2018.3264

To the Editor We noted with interest the findings of Ben-Aharon et al1 regarding the application of the American Society of Clinical Oncology Net Health Benefit Criteria for tail-of-the-curve credits among immunotherapy studies. The findings do not surprise, partly because the time point of twice the median survival of the control arm in immunotherapy studies is more often at the shoulder of the curve rather than the true tail of the survival curve. This substantially compromises the ability to detect the long-term gains that are best observed at the true tail.

Add or change institution